SCHEMBL5187673

SCHEMBL5187673

CCOC(=O)C1=CC=CCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.40
CA12 O43570 6/20 0.38
CA1 P00915 6/20 0.38
CA2 P00918 6/20 0.38
CA7 P43166 6/20 0.38
CA9 Q16790 6/20 0.38
CA14 Q9ULX7 6/20 0.38
ESR1 P03372 1/20 0.38
ESR2 Q92731 1/20 0.38
CYP1A2 P05177 2/20 0.37
LMNA P02545 2/20 0.37
MAPT P10636 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ALOX15 P16050 1/20 0.37
NR1H2 P55055 1/20 0.37
NR1H3 Q13133 1/20 0.37
CYP3A4 P08684 1/20 0.37
MAOA P21397 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8590618 0.90 TSHR (0.38) TSHRCA12CA1CA2CA7
SCHEMBL11801347 0.87 KDM4E (0.36) TSHRCA12CA1CA2CA7
SCHEMBL11801338 0.87 KDM4E (0.36) TSHRCA12CA1CA2CA7
SCHEMBL11801341 0.87 KDM4E (0.36) TSHRCA12CA1CA2CA7
SCHEMBL3577333 0.83 TSHR (0.46) TSHRESR1CYP1A2LMNAMAPT
SCHEMBL8947546 0.83 TSHR (0.48) TSHRCA12CA1CA2CA7
SCHEMBL28417053 0.83 TSHR (0.48) TSHRCA12CA1CA2CA7
SCHEMBL6970357 0.82
SCHEMBL6966305 0.81
SCHEMBL43932 0.81

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1569965-B1 METHOD FOR RADICAL POLYMERISATION IN THE PRESENCE OF A CHAIN TRANSFER AGENT BASF AG (DE) 2007-07-11 EP claimed
US-7196150-B2 Method for radical polymerisation in the presence of a chain transfer agent BASF AKTIENGESELLSCHAFT (DE) 2007-03-27 US claimed
US-20060058478-A1 Method for radical polymerisation in the presence of a chain transfer agent BASF AKTIENGESELLSCHAFT (DE) 2006-03-16 US claimed
US-8163761-B2 Methods and compositions for treating disorders HYDRA BIOSCIENCES, INC. (US) 2012-04-24 US disclosed
US-20120046305-A1 METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISORDERS ELI LILLY AND COMPANY 2012-02-23 US disclosed
US-20090143377-A1 METHODS AND COMPOSITIONS FOR TREATING DISORDERS ELI LILLY AND COMPANY 2009-06-04 US disclosed
CN-1307171-C Benzopyrans and benzothiopyrans, pharmaceutical compositions containing them and process for their preparation MERCK PATENT GMBH (DE) 2007-03-28 CN disclosed
CN-1554651-A Benzopyrans and benzothiopyrans, pharmaceutical compositions containing them and process for their preparation Ĭ��ר���ɷ����޹�˾ 2004-12-15 CN disclosed
CN-1173967-C Benzopyran and benzoxepin *, pharmaceutical compositions containing them and process for preparing them Ĭ��ר���ɷ����޹�˾ 2004-11-03 CN disclosed
CN-1359383-A Benzopyran and benzoxepin *, pharmaceutical compositions containing them and process for preparing them MERCK PATENT GMBH (DE) 2002-07-17 CN disclosed
US-5990122-A SUBSTITUTED IN THE 7-POSITION BY A TRICYCLIC AMINE RADICAL; REDUCED GENOTOXIC PROPERTIES AND INCREASED ANTIBACTERIAL ACTIVITY BAYER AKTIENGESELLSCHAFT (DE) 1999-11-23 US disclosed
US-5986105-A ENANTIOMORPHS AS BACTERICIDES BAYER AKTIENGESELLSCHAFT (DE) 1999-11-16 US disclosed
US-5753669-A BACTERICIDES BAYER AKTIENGESELLSCHAFT (DE) 1998-05-19 US disclosed
US-5605910-A BACTERICIDES BAYER AKTIENGESELLSCHAFT (DE) 1997-02-25 US disclosed
EP-0609289-B1 IMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME UPJOHN CO (US) 1996-07-17 EP disclosed
US-5442062-A Treating hypertension, congestive heart failure THE UPJOHN COMPANY (US) 1995-08-15 US disclosed
EP-0540209-A1 Imidazole derivatives and pharmaceutical compositions containing the same THE UPJOHN COMPANY (US) 1993-05-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143377-A1 METHODS AND COMPOSITIONS FOR TREATING DISORDERS TRPA1, TRPV1, TRPV3 TSHR 3225/4885CA12 2010/4885CA1 1049/4885
US-20120046305-A1 METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISORDERS TRPA1, TRPV1, TRPV3 TSHR 3294/4885CA12 1344/4885CA1 1342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.